At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VANI Vivani Medical, Inc.
Market Closed 11-22 16:00:00 EST
1.34
+0.01
+0.75%
盘后1.33
-0.01-0.75%
19:42 EST
High1.37
Low1.30
Vol100.74K
Open1.32
D1 Closing1.33
Amplitude5.26%
Mkt Cap79.37M
Tradable Cap36.98M
Total Shares59.23M
T/O134.60K
T/O Rate0.37%
Tradable Shares27.59M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Independent Chairman of the Board of Vivani Medical Gregg Williams Buys 30% More Shares
BRIEF-Vivani Medical Receives Regulatory Approval To Initiate First In Human Clinical Trial With Glp-1 Implant In Obese And Overweight Individuals In Australia
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial With Glp-1 Implant in Obese and Overweight Individuals in Australia
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.